GoodRx's Recent Share Price Decline: Is the Company Undervalued or Overvalued?

GoodRx Holdings (GDRX) shares have declined 27% over the past month, with a one-year total shareholder return of -36.4%. The company's recent downward momentum and caution from investors raise questions about its value. Despite the decline, GoodRx's narrative points to a fair value far above its recent close, highlighting upside potential based on future earnings and cash flows. Major shifts in pharmacy partnerships or regulatory changes could disrupt its growth story.